Back to Search
Start Over
Ozenoxacin: A Novel Drug Discovery for the Treatment of Impetigo
- Source :
- Current drug discovery technologies. 16(3)
- Publication Year :
- 2018
-
Abstract
- Objective: Ozenoxacin is one of the potent quinolone antibiotics, recently approved by the United States Food and Drug Administration (USFDA) with reported pharmacology to treat the impetigo. The demand for better acting topical formulation is increasing day by day. The present review is an attempt to summarize the facts behind the chemistry and biological applications of Ozenoxacin. Mechanism of Action: This novel drug being a quinolone antibiotic compound, acts by inhibiting DNA gyrase A and topoisomerase IV and affects supercoiling, supercoil relaxation, chromosomal condensation, chromosomal decatenation and many others. Mechanism of Action: This novel drug being a quinolone antibiotic compound, acts by inhibiting DNA gyrase A and topoisomerase IV and affects supercoiling, supercoil relaxation, chromosomal condensation, chromosomal decatenation and many others. Pharmacology: Ozenoxacin has demonstrated to have a bactericidal activity against organisms, such as Staphylococcus aureus and Staphylococcus pyogenes. Ozenoxacin is non-fluorinated quinolone and being developed for the other dermatological bacterial infections as well. No sign of genotoxicity was observed when tested experimentally. Conclusion: The present review also covers the complete picture of pharmacokinetics, clinical trials, toxicity and future scope and possible avenues in this arena.
- Subjects :
- 0301 basic medicine
Drug
Impetigo
Topoisomerase IV
medicine.drug_class
media_common.quotation_subject
030106 microbiology
Antibiotics
Aminopyridines
Pharmacology
Quinolones
DNA gyrase
030207 dermatology & venereal diseases
03 medical and health sciences
0302 clinical medicine
Drug Discovery
medicine
Animals
Humans
Drug Interactions
media_common
biology
Drug discovery
medicine.disease
Quinolone
Anti-Bacterial Agents
biology.protein
Ozenoxacin
Subjects
Details
- ISSN :
- 18756220
- Volume :
- 16
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Current drug discovery technologies
- Accession number :
- edsair.doi.dedup.....8c0c1bcb6ae06f67468d326c0105e8d6